Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Cited by (1,077)

Items 201–300 of 1,077

1. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions
   Christopher A. Lipinski · 2016 · Advanced Drug Delivery Reviews
2. Diverse, High-Quality Test Set for the Validation of Protein−Ligand Docking Performance
   Michael J. Hartshorn, Marcel L. Verdonk, Gianni Chessari, Suzanne Clare Brewerton, Wijnand T. M. Mooij, Paul N. Mortenson, Christopher W. Murray · 2007 · Journal of Medicinal Chemistry
3. BCL-2 family antagonists for cancer therapy
   Guillaume Lessène, Peter E. Czabotar, Peter M. Colman · 2008 · Nature Reviews Drug Discovery
4. Natural Products as Platforms To Overcome Antibiotic Resistance
   Rossiter, Sean E., Fletcher, Madison H., Wuest, William M. · 2017 · Chemical Reviews
5. Nanotechnology for the biologist
   Scott E. McNeil · 2005 · Journal of Leukocyte Biology
6. Identification of an antimalarial synthetic trioxolane drug development candidate
   Jonathan L. Vennerstrom, Sarah Arbe‐Barnes, Reto Brun, Susan A. Charman, Francis C. K. Chiu, Jacques Chollet, Yuxiang Dong, A Dorn, Daniel Hunziker, Hugues Matile et al. · 2004 · Nature
7. Nanocarriers for cancer-targeted drug delivery
   Preeti Kumari, Balaram Ghosh, Swati Biswas · 2015 · Journal of drug targeting
8. Hit and lead criteria in drug discovery for infectious diseases of the developing world
   Kei Katsuno, Jeremy Nicholas Burrows, Ken Duncan, Rob Hooft van Huijsduijnen, Takushi Kaneko, Kiyoshi Kita, Charles E. Mowbray, Dennis M. Schmatz, Peter Warner, B. T. Slingsby · 2015 · Nature Reviews Drug Discovery
9. Diversity-oriented synthesis: Exploring the intersections between chemistry and biology
   Tan, Derek S · 2005 · Nature Chemical Biology
10. Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade
    Masha G. Savelieff, Geewoo Nam, Juhye Kang, Hyuck Jin Lee, Misun Lee, Mi Hee Lim · 2018 · Chemical Reviews
11. Caco-2 cell permeability assays to measure drug absorption
    Richard Bruce van Breemen, Yongmei Li · 2005 · Expert Opinion on Drug Metabolism & Toxicology
12. A Specific Mechanism of Nonspecific Inhibition
    Susan Lynne McGovern, Brian T. Helfand, Brian Y. Feng, Brian K. Shoichet · 2003 · Journal of Medicinal Chemistry
13. Computer-Aided Drug Design Methods
    Wenbo Yu, Alexander D. MacKerell · 2016 · Methods in molecular biology
14. Targeting RNA structures with small molecules
    Jessica L. Childs‐Disney, Xueyi Yang, Quentin M. R. Gibaut, Yuquan Tong, Robert Batey, Matthew David Disney · 2022 · Nature Reviews Drug Discovery
15. SuperPred: update on drug classification and target prediction
    Janette Nickel, Björn-Oliver Gohlke, Jevgeni Erehman, Priyanka Banerjee, Wen Wei Rong, Andrean Goede, Mathias Dunkel, Robert Preißner · 2014 · Nucleic Acids Research
16. Physicochemical Profiling (Solubility, Permeability and Charge State)
    Alex Avdeef · 2001 · Current Topics in Medicinal Chemistry
17. Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, and H-Bonding Descriptors
    H. Van De Waterbeemd, Gian Camenisch, Gerd Folkers, Jacques R. Chrétien, Oleg A. Raevsky · 1998 · Journal of drug targeting
18. Computational methods for the prediction of ‘drug-likeness’
    David E. Clark, Stephen D. Pickett · 2000 · Drug Discovery Today
19. Discovery of small molecule cancer drugs: Successes, challenges and opportunities
    Swen Hoelder, Paul Andrew Clarke, Paul Workman · 2012 · Molecular Oncology
20. CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
    Zoran Ranković · 2014 · Journal of Medicinal Chemistry
21. The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate
    Guy Van den Mooter · 2011 · Drug Discovery Today Technologies
22. Understanding Cell Penetration of Cyclic Peptides
    Patrick G. Dougherty, Ashweta Sahni, Dehua Pei · 2019 · Chemical Reviews
23. Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It
    Helen I. Zgurskaya, César A. López, Sandrasegaram Gnanakaran · 2015 · ACS Infectious Diseases
24. Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review
    Tiejun Cheng, Qingliang Li, Zhigang Zhou, Yanli Wang, Stephen H. Bryant · 2012 · The AAPS Journal
25. Drug delivery strategies for poorly water-soluble drugs
    Alfred Fahr, Xiangli Liu · 2007 · Expert Opinion on Drug Delivery
26. Systems biology and combination therapy in the quest for clinical efficacy
    Fitzgerald, Jonathan B, Schoeberl, Birgit, Nielsen, Ulrik B, Sorger, Peter K · 2006 · Nature Chemical Biology
27. When poor solubility becomes an issue: From early stage to proof of concept
    Sven Stegemann, Franck Leveiller, Dionigio Franchi, H. de Jong, Hans H. Lindén · 2007 · European Journal of Pharmaceutical Sciences
28. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
    Robert Jr. Roskoski · 2019 · Pharmacological Research
29. Targeting lipophilic cations to mitochondria
    Murphy, Michael P. · 2008 · Biochimica et Biophysica Acta (BBA) - Bioenergetics
30. Discovery of IDO1 Inhibitors: From Bench to Bedside
    George C. Prendergast, William P. Malachowski, James B. DuHadaway, Alexander J. Muller · 2017 · Cancer Research
31. Chemical genetics of Plasmodium falciparum
    W. Armand Guiguemde, Anang A. Shelat, David C. Bouck, Sandra Duffy, Gregory J. Crowther, Paul H. Davis, David C. Smithson, Michele Connelly, Julie A. Clark, Fangyi Zhu et al. · 2010 · Nature
32. Prodrug strategies to overcome poor water solubility
    Valentino J. Stella, Kwame W. Nti-Addae · 2007 · Advanced Drug Delivery Reviews
33. A drug-likeness toolbox facilitates ADMET study in drug discovery
    Chen‐Yang Jia, Jingyi Li, Ge‐Fei Hao, Guang‐Fu Yang · 2019 · Drug Discovery Today
34. Properties of FDA-approved small molecule protein kinase inhibitors
    Roskoski, Robert · 2019 · Pharmacological Research
35. Predicting plasma protein binding of drugs: a new approach
    Nicole A. Kratochwil, Walter Huber, Francis Müller, Manfred Kansy, Paul R. Gerber · 2002 · Biochemical Pharmacology
36. Metal complexes as a promising source for new antibiotics
    Angelo Frei, Johannes Zuegg, Alysha G. Elliott, Murray V. Baker, Stefan Braese, Christopher Brown, Feng Chen, Christopher Gerard Dowson, Gilles Dujardin, Nicole Jung et al. · 2020 · Chemical Science
37. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
    Mark John Millan · 2006 · Pharmacology & Therapeutics
38. Emerging therapeutic opportunities for integrin inhibitors
    Robert J. Slack, Simon J. F. Macdonald, James A. Roper, Gisli R. Jenkins, Richard J. D. Hatley · 2021 · Nature Reviews Drug Discovery
39. Fluorescence Study of the Curcumin−Casein Micelle Complexation and Its Application as a Drug Nanocarrier to Cancer Cells
    Abhishek Sahu, Naresh Kasoju, Utpal Bora · 2008 · Biomacromolecules
40. Stimuli-Responsive Nanomaterials for Biomedical Applications
    Angela P. Blum, Jacquelin K. Kammeyer, Anthony M. Rush, Cassandra E. Callmann, Michael E. Hahn, Nathan C. Gianneschi · 2014 · Journal of the American Chemical Society
41. Targeted polymeric micelles for delivery of poorly soluble drugs
    Vladimir P. Torchilin · 2004 · Cellular and Molecular Life Sciences
42. Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I
    Turner, Nigel, Li, Jing-Ya, Gosby, Alison, To, Sabrina W.C., Cheng, Zhe, Miyoshi, Hiroyuki, Taketo, Makoto M., Cooney, Gregory J., Kraegen, Edward W., James, David E. et al. · 2008 · Diabetes
43. Targeting dual-specificity phosphatases: Manipulating MAP kinase signalling and immune responses
    Jeffrey, Kate L., Camps, Montserrat, Rommel, Christian, Mackay, Charles R. · 2007 · Nature Reviews Drug Discovery
44. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors
    Yuan Hui Zhao, Joelle Le, Michael H. Abraham, Anne Hersey, Peter J. Eddershaw, Chris N. Luscombe, Darko Boutina, Gordon Beck, Brad S. Sherborne, Ian Cooper et al. · 2001 · Journal of Pharmaceutical Sciences
45. High-throughput crystallography for lead discovery in drug design
    Tom L. Blundell, Harren Jhoti, Chris Abell · 2002 · Nature Reviews Drug Discovery
46. Spray drying formulation of amorphous solid dispersions
    Abhishek K. Singh, Guy Van den Mooter · 2015 · Advanced Drug Delivery Reviews
47. Venoms as a platform for human drugs: translating toxins into therapeutics
    Glenn F. King · 2011 · Expert Opinion on Biological Therapy
48. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood–brain barrier penetration
    David E. Clark · 1999 · Journal of Pharmaceutical Sciences
49. Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs
    Roberta Censi, Piera Di Martino · 2015 · Molecules
50. Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
    Altenhöfer, Sebastian, Radermacher, Kim A., Kleikers, Pamela W.M., Wingler, Kirstin, Schmidt, Harald H.H.W. · 2015 · Antioxidants & Redox Signaling
51. On the binding affinity of macromolecular interactions: daring to ask why proteins interact
    Panagiotis L. Kastritis, Alexandre M. J. J. Bonvin · 2012 · Journal of The Royal Society Interface
52. Evaluation of amorphous solid dispersion properties using thermal analysis techniques
    Jared A. Baird, Lynne S. Taylor · 2011 · Advanced Drug Delivery Reviews
53. Dry Powder Inhaler Formulation
    Martin J Telko, Anthony James Hickey · 2005 · Respiratory Care
54. Pursuing the leadlikeness concept in pharmaceutical research
    Mike M. Hann, Tudor Ionel Oprea · 2004 · Current Opinion in Chemical Biology
55. Probing the links between in vitro potency, ADMET and physicochemical parameters
    M. Paul Gleeson, Anne Hersey, Dino Montanari, John P. Overington · 2011 · Nature Reviews Drug Discovery
56. Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors
    Jie-Lou Liao · 2007 · Journal of Medicinal Chemistry
57. Antibacterial Nanomaterials: Mechanisms, Impacts on Antimicrobial Resistance and Design Principles
    Maomao Xie, Meng Gao, Yang Sik Yun, Martin Malmsten, Vincent M. Rotello, Radek Zbořil, Omid Akhavan, Aliaksandr N. Kraskouski, John Amalraj, Xiaoming Cai et al. · 2023 · Angewandte Chemie International Edition
58. The application of in silico drug-likeness predictions in pharmaceutical research
    Sheng Tian, Junmei Wang, Youyong Li, Dan Li, Lei Xu, Tingjun Hou · 2015 · Advanced Drug Delivery Reviews
59. Polymeric nanomedicine for cancer therapy
    Park, Jae Hyung, Lee, Seulki, Kim, Jong-Ho, Park, Kyeongsoon, Kim, Kwangmeyung, Kwon, Ick Chan · 2008 · Progress in Polymer Science
60. Artificial intelligence for natural product drug discovery
    Michael W. Mullowney, Katherine Duncan, Somayah S. Elsayed, Neha Garg, Justin J. J. van der Hooft, Nathaniel I. Martin, David Meijer, Barbara R. Terlouw, Friederike Biermann, Kai Blin et al. · 2023 · Nature Reviews Drug Discovery
61. ChemMine tools: an online service for analyzing and clustering small molecules
    Tyler W. H. Backman, Y. Cao, Thomas Girke · 2011 · Nucleic Acids Research
62. QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery
    Bruno J. Neves, Rodolpho C. Braga, Cleber Camilo Melo-Filho, José Teófilo Moreira‐Filho, Eugene N. Muratov, Carolina Horta Andrade · 2018 · Frontiers in Pharmacology
63. Drug discovery from plant sources: An integrated approach
    Chandra Kant Katiyar, Satyajyoti Kanjilal, Arun Kumar Gupta, Shefali Katiyar · 2012 · AYU (An International Quarterly Journal of Research in Ayurveda)
64. N‐Methylation of Peptides and Proteins: An Important Element for Modulating Biological Functions
    Jayanta Chatterjee, Florian Rechenmacher, Horst Kessler · 2012 · Angewandte Chemie International Edition
65. Bridging solubility between drug discovery and development
    Li Di, Paul V. Fish, Takashi Mano · 2011 · Drug Discovery Today
66. Human Intestinal Permeability
    Hans Lennernäs · 1998 · Journal of Pharmaceutical Sciences
67. Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes
    Travis T. Wager, Ramalakshmi Yegna Chandrasekaran, Xinjun Hou, Matthew D. Troutman, Patrick R. Verhoest, Anabella Villalobos, Yvonne Will · 2010 · ACS Chemical Neuroscience
68. Small-Molecule Fluorescent Probes for Live-Cell Super-Resolution Microscopy
    Lu Wang, Michelle S. Frei, Aleksandar Salim, Kai Johnsson · 2018 · Journal of the American Chemical Society
69. The chemistry and biotransformation of tea constituents
    Sang, Shengmin, Lambert, Joshua D., Ho, Chi-Tang, Yang, Chung S. · 2011 · Pharmacological Research
70. Do enthalpy and entropy distinguish first in class from best in class?
    Freire, Ernesto · 2008 · Drug Discovery Today
71. Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
    Churcher, Ian · 2018 · Journal of Medicinal Chemistry
72. Testing the Conformational Hypothesis of Passive Membrane Permeability Using Synthetic Cyclic Peptide Diastereomers
    Taha Rezai, Bin Yu, Glenn L. Millhauser, Matthew P. Jacobson, R. Scott Lokey · 2006 · Journal of the American Chemical Society
73. Volitional aspects of achievement motivation and learned helplessness: toward a comprehensive theory of action control.
    Julius Kühl · 1984 · PubMed
74. Rings in Clinical Trials and Drugs: Present and Future
    Jonathan Shearer, José L. Castro, Alastair D. G. Lawson, Malcolm MacCoss, Richard D. Taylor · 2022 · Journal of Medicinal Chemistry
75. Mechanisms of Cancer Prevention by Tea Constituents
    Joshua D. Lambert, Chung Shu Yang · 2003 · Journal of Nutrition
76. The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds
    Andrea Calcaterra, Ilaria D’Acquarica · 2017 · Journal of Pharmaceutical and Biomedical Analysis
77. Macrocycles In New Drug Discovery
    Jamie Mallinson, Ian Collins · 2012 · Future Medicinal Chemistry
78. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
    Feng Zhu, Zhe Shi, C. Qin, Lin Tao, Xin Liu, Feng Xu, Lexing Zhang, Y. Song, Xin Liu, Jingjie Zhang et al. · 2011 · Nucleic Acids Research
79. Complement-targeted therapeutics
    Daniel Ricklin, John D. Lambris · 2007 · Nature Biotechnology
80. Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs
    James A. Seidler, Susan Lynne McGovern, Thompson N. Doman, Brian K. Shoichet · 2003 · Journal of Medicinal Chemistry
81. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
    Dobson, Paul D., Kell, Douglas B. · 2008 · Nature Reviews Drug Discovery
82. Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution
    David E. Alonzo, Geoff G. Z. Zhang, Deliang Zhou, Yi Gao, Lynne S. Taylor · 2010 · Pharmaceutical Research
83. Exploring biology with small organic molecules
    Brent R. Stockwell · 2004 · Nature
84. Methods to Explore Cellular Uptake of Ruthenium Complexes
    Cindy A. Puckett, Jacqueline K. Barton · 2006 · Journal of the American Chemical Society
85. Overview of milling techniques for improving the solubility of poorly water-soluble drugs
    Zhi Hui Loh, Asim Kumar Samanta, Paul Wan Sia Heng · 2015 · Asian Journal of Pharmaceutical Sciences
86. Molecular Docking and High-Throughput Screening for Novel Inhibitors of Protein Tyrosine Phosphatase-1B
    Thompson N. Doman, Susan Lynne McGovern, Bryan J. Witherbee, Thomas P. Kasten, Ravi G. Kurumbail, William C. Stallings, Daniel T. Connolly, Brian K. Shoichet · 2002 · Journal of Medicinal Chemistry
87. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds
    Ronald Scott Obach, Franco Lombardo, Nigel J. Waters · 2008 · Drug Metabolism and Disposition
88. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
    Wu, Peng, Nielsen, Thomas E., Clausen, Mads H. · 2016 · Drug Discovery Today
89. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
    Arup K. Ghose, Torsten Herbertz, Robert L. Hudkins, Bruce D. Dorsey, John P. Mallamo · 2011 · ACS Chemical Neuroscience
90. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
    Jens Wagner, Sergey Ryazanov, Andrei Leonov, Johannes Levin, Song Shi, Felix Schmidt, Catharina Prix, Francisco J. Pan-Montojo, Uwe Bertsch, Gerda Mitteregger-Kretzschmar et al. · 2013 · Acta Neuropathologica
91. Virtual Exploration of the Chemical Universe up to 11 Atoms of C, N, O, F: Assembly of 26.4 Million Structures (110.9 Million Stereoisomers) and Analysis for New Ring Systems, Stereochemistry, Physicochemical Properties, Compound Classes, and Drug Discovery
    Tobias Fink, Jean‐Louis Reymond · 2007 · Journal of Chemical Information and Modeling
92. The role of the medicinal chemist in drug discovery — then and now
    Joseph G. Lombardino, John A. Lowe III · 2004 · Nature Reviews Drug Discovery
93. Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
    Hang Hubert Yin, Andrew D. Hamilton · 2005 · Angewandte Chemie International Edition
94. An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity
    David J. Haydon, Neil R. Stokes, Rebecca Ure, Greta Galbraith, James M. Bennett, David R. Brown, Patrick J. Baker, Vladimir V. Barynin, David W. Rice, Sveta E. Sedelnikova et al. · 2008 · Science
95. Absorption and Drug Development: Solubility, Permeability, and Charge State
    Alex Avdeef · 2003
96. Orally Absorbed Cyclic Peptides
    Daniel S. Nielsen, Nicholas E. Shepherd, Weijun Xu, Andrew J. Lucke, Martin J. Stoermer, David P. Fairlie · 2017 · Chemical Reviews
97. An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
    Kyle D. Konze, Anqi Ma, Fengling Li, Dalia Baršytė-Lovejoy, Trevor Parton, Christopher J. MacNevin, Feng Liu, Cen Gao, Xi‐Ping Huang, Ekaterina Kuznetsova et al. · 2013 · ACS Chemical Biology
98. Drug Targeting to the Brain
    William M. Pardridge · 2007 · Pharmaceutical Research
99. Medicating the environment: assessing risks of pharmaceuticals to wildlife and ecosystems
    Kathryn E. Arnold, Andrew Ross Brown, Gerald T. Ankley, John P. Sumpter · 2014 · Philosophical Transactions of the Royal Society B Biological Sciences
100. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen
     David Plouffe, Achim Brinker, Case W. McNamara, Kerstin Henson, Nobutaka Kato, Kelli Kuhen, Advait S. Nagle, Francisco Adrián, Jason Matzen, Paul Anderson et al. · 2008 · Proceedings of the National Academy of Sciences